2026-06-08T11:06:38Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1261622025-11-19T00:49:14Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Lens, Sabela author García Eliz, María author Fernández Vázquez, María Inmaculada author Castells, Lluis author Bonacci, Martin author Mas, Antoni author Crespo, Gonzalo author Buti, María author Prieto, Martín author Forns, Xavier author 2018-04-01 Background & Aims: The combination of hepatitis B immunoglobulin and a nucleos(t)ide analogues has markedly reduced the rate of hepatitis B virus recurrence after liver transplantation; however, the optimal duration of hepatitis B immunoglobulin has not been clarified. This lack of consensus perpetuates the use of different strategies. The aim of this study was to evaluate the risk factors associated to hepatitis B virus recurrence after liver transplantation in a large cohort of patients under different hepatitis B immunoglobulin regimens. Methods: Retrospective multicentre analysis of hepatitis B virus-related liver transplantation recipients receiving combined prophylaxis (hepatitis B immunoglobulin + nucleos(t)ide analogues). The strategy of short-term hepatitis B immunoglobulin was compared to lifelong administration. Hepatitis B virus recurrence was defined as positive HBsAg after liver transplantation. Results: Three hundred and thirty-eight patients were analysed. After a median follow-up period of 72 months, 37 patients (11%) developed hepatitis B virus recurrence. Hepatocellular carcinoma recurrence and lamivudine resistance after liver transplantation were the only factors independently associated to hepatitis B virus recurrence (HR 5.4 [2.3-12] and 9.3 [4.2-20] respectively P < .001). HBsAg reappearance after hepatitis B virus recurrence was transient (16 patients), persistent (15) or alternant (6). The hepatitis B immunoglobulin regimen did not have an impact on the rate or evolution of hepatitis B virus recurrence. Overall, patient survival was good and not influenced by hepatitis B virus recurrence (82% at 5 years). Fulminant liver failure, hepatitis C coinfection or hepatocellular carcinoma at liver transplantation were independent risk factors for lower survival. Conclusions: Liver transplantation is an effective treatment for hepatitis B virus-related liver disease. Since the introduction of combined prophylaxis the rate of hepatitis B virus recurrence is very low. However, lifelong hepatitis B immunoglobulin administration does not seem necessary to reduce hepatitis B virus recurrence. Lens S, García-Eliz M, Fernández I, Castells LL, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X. Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int. 2018 Abr;38 (11):1940–1950. 1478-3223 doi.org/10.1111/liv.13858 https://hdl.handle.net/20.500.14352/126162 1478-3231 https://doi.org/10.1111/liv.13858 29660249 https://onlinelibrary.wiley.com/doi/10.1111/liv.13858 https://pubmed.ncbi.nlm.nih.gov/29660249/ Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation